Dholaria, B., Bahlis, N., Raje, N., Costello, C., Solh, M., Levy, M., … Lesokhin, A. (2021). OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM). In Clinical Lymphoma Myeloma and Leukemia (Vol. 21, pp. S17–S17). Elsevier BV. https://doi.org/10.1016/s2152-2650(21)02100-5

Dholaria, Bhagirathbhai, Nizar Bahlis, Noopur Raje, Caitlin Costello, Melhem Solh, Moshe Levy, Michael Tomasson, et al. “OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM).” In Clinical Lymphoma Myeloma and Leukemia, 21:S17–S17. Elsevier BV, 2021. https://doi.org/10.1016/s2152-2650(21)02100-5.

Dholaria B, Bahlis N, Raje N, Costello C, Solh M, Levy M, et al. OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM). In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2021. p. S17–S17.

Dholaria, Bhagirathbhai, et al. “OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM).” Clinical Lymphoma Myeloma and Leukemia, vol. 21, Elsevier BV, 2021, pp. S17–S17. Crossref, doi:10.1016/s2152-2650(21)02100-5.

Dholaria B, Bahlis N, Raje N, Costello C, Solh M, Levy M, Tomasson M, Dube H, Damore M, Lon HK, Basu C, Skoura A, Chan E, Trudel S, Jakubowiak A, Chu M, Gasparetto C, Dalovisio A, Sebag M, Lesokhin A. OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM). Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2021. p. S17–S17.